Kristen A. Gerjevic, MD, MPH

Department

Obstetrics & Gynecology

Position

Affiliate Assistant Professor

Articles

• Urogynecology
  Sripad AA,, Gerjevic KA, Duong V, Askew A, Clark SG, Woodburn KL, Maetzold E, Raker CA, Rardin CA Risk of Recurrent Prolapse by Extent of Mesh Excisions Procedures: A Multicenter Study Importance There is limited evidence guiding surgeons in how much mesh to resect when treating mesh complications. Objective The aim of the study was to compare rates of recurrent prolapse after mesh excisional surgical procedures for prolapse mesh complications. Study Design This multicenter, retrospective cohort study included patients, identified by Current Procedural Terminology codes, who were treated surgically for prolapse mesh complications at 8 institutions between 2010 and 2019. Excisional surgical procedures were categorized as major (total vaginal, extravaginal, and total mesh excisions) or minor (partial vaginal excisions and mesh revisions). The primary outcome was prolapse recurrence 1 year after mesh excision surgery. Secondary outcomes included long-term prolapse recurrence. Prolapse recurrence was evaluated by Kaplan-Meier survival analysis and Cox proportional hazards regression. Results Two hundred sixty-one patients met inclusion criteria with 188 (72%) undergoing minor and 73 (28%) major excisions, with a median follow-up time of 1.0 years. Groups differed in parity, location of implant surgery, and number of vaginal compartments involved in excision. Within the first year, major excisions had a higher prolapse recurrence rate (8.7%) than minor excisions (2.9%), P < 0.05. Adjusting for mesh implant type, the hazard ratio for pelvic organ prolapse was 6.1 in the major compared to minor excision. In the entire study period, prolapse recurrence was 33.8% and did not differ between groups. Conclusions Patients undergoing major excision surgical procedures may have higher rates of prolapse at 1 year compared to those undergoing minor excisions. However, in long-term follow-up, recurrence rates were not different. Our findings may aid surgeons in expectation setting prior to excisional procedures.
  31, p. 535-544 2024
• Current Geriatric Rep
  Cooper AC, Gerjevic KA Botox Use in the Older Woman: An Advanced Bladder Treatment Option Purpose of Review This article focuses on challenges of caring for older women with urgency urinary incontinence (UUI), and asks how treatment algorithms for UUI could be tailored to the needs of older women. Recent Findings Urgency urinary incontinence is highly prevalent among older women, and has significant health, social and economic impact for patients, caregivers and society. It is more difficult to treat among older women in part due to interaction with other geriatric syndromes and comorbidities. Also, the existing treatment algorithm, including anticholinergic medications as a mainstay of therapy, is less relevant to older patients due to increased risks and limitations of all therapies. Use of onabotulinumtoxinA treatment may have a more favorable risk/benefit profile compared with other therapies, and merits consideration earlier in the treatment of older women with UUI. Summary Urgency urinary incontinence is more difficult to treat among older women, and an updated treatment algorithm is needed to meet existing and increasing need. Use of first-line therapies and beta agonists should be supported among primary care providers to accelerate access to care. Subspecialty providers should give earlier consideration of bladder onabotulintumtoxinA (BOTOX©) treatment prior to or instead of oral medications, in part because of its lower systemic side effects, favorable cost profile, and versatility of dosing. Other third line therapies remain applicable as well but have more fixed disadvantages among older patients. Research is needed to scrutinize the outcomes, side effects, and experience of BTX treatment among older women, and more broadly, to query the influence of factors such as frailty, comorbidities, dementia and polypharmacy on response to treatment of UUI.
  2, p. 1-12 2023
• American Journal of Obstetrics and Gynecology
  Shanahan M, Gerjevic KA, Emeny RT, Considine E, Trevina E, Reigh E. Shanahan M, Gerjevic KA, Emeny RT, Considine E, Trevina E, Reigh E. Improving Antibiotic Use During Delivery Hospitalizations with the use of Penicillin Allergy Testing in Prenatal Care. Am J Obstet Gynecol MFM. 2022 Oct 7;5(1):100765. Epub ahead of print. PMID: 362 16313
  5 2022
• Journal of Minimally Invasive Gynecology
  Shaw JS, Gerjevic KA, Pollack C, Strohbehn K. Shaw JS, Gerjevic KA, Pollack C, Strohbehn K. Minimally-invasive autologous fascia sling at the mid-urethra: a case series. J Minim Invasive Gynecol. 2022 Jul 6:S1553-4650(22)00267-9. doi: 10.1016/j.jmig.2022.07.001. Epub ahead of print. PMID: 35809894.
  S1553-4650(22), p. 00267-00269 2022
• Female Pelvic Med Reconstructive Surgery
  Gerjevic KA, Brandes E, Gormley EA, Auty SG, Strohbehn K Gerjevic KA, Brandes E, Gormley EA, Auty SG, Strohbehn K. Trends Among Female Pelvic Medicine and Reconstructive Surgery Fellowships and Graduates. Female Pelvic Med Reconstr Surg. 2022 Apr 15. PMID 35421016
  28, p. e211-e214 2022
• Obstetrics and Gynecology
  Gerjevic KA, Newton H, Leggett C, Skinner J, Erekson E, Strohbehn K. Gerjevic KA, Newton H, Leggett C, Skinner J, Erekson E, Strohbehn K. Geographic Variation in Apical Support Procedures for Pelvic Organ Prolapse. Obstet Gynecol. 2022 Mar 10. PMID 35272346
  139, p. 597-605 2022
• Female Pelvic Med Reconstructive Surgery
  Gerjevic KA, Ahmad S, Strohbehn K, Riblet N. Gerjevic KA, Ahmad S, Strohbehn K, Riblet N. Cost-effectiveness analysis between sacral neuromodulation and onabotulinumtoxinA for the treatment of refractory overactive bladder in women: A Systematic Review. Female Pelvic Med Reconstr Surg 2021 Aug 1;27(8):481-487. PMID: 34074937
  27, p. 481-487 2021
• Obstetrics and Gynecology
  Damiano EA, Auty S, Von Mertens J, Gerjevic, KA. Damiano EA, Auty S, Von Mertens J, Gerjevic, KA. Singleton, Term, Vertex Cesarean Delivery on a Midwife Service Compared with an Obstetrician Service. Obstet Gynecol. 2020 Jun;135(6):1353-1361. PMID: 32459427
  135, p. 1353-1361 2020
• Female Pelvic Med Reconstructive Surgery
  Gerjevic KA, Erekson E, Strohbehn K, Jacobs KA, Hanissian PD, Aarts JWM Gerjevic KA, Erekson E, Strohbehn K, Jacobs KA, Hanissian PD, Aarts JWM. Patient Information Priorities for Deciding on Treatment of Pelvic Organ Prolapse. Female Pelvic Med Reconstr Surg. 2018 Feb 28.
  5, p. 372-377 2019
• Stroke
  Shen Y, Bodary PF, Vargas FB, Homeister JW, Gordon D, Ostenso KA, Shayman JA, Eitzman DT Shen Y, Bodary PF, Vargas FB, Homeister JW, Gordon D, Ostenso KA, Shayman JA, Eitzman DT. Alpha-galactosidase A deficiency leads to increased tissue fibring deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke 2006 Apr;37(4):1106-8
  37, p. 1106-1108 2006
• Circulation
  Peter F Bodary, Yuechun Shen, Fernando B Vargas, Xiaoming Bi, Kristen A Ostenso, Shufang Gu, James A Shayman, Daniel T Eitzman 2. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA, Eitzman DT. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency Circulation 2005 Feb 8, 111(5):629-32.
  111, p. 629-632 2005

Publications

• BMC Medicine
  Gerjevic KA, Rosenbaum ME, Suneja M. Gerjevic KA, Rosenbaum ME, Suneja M. Resident Perceptions of the Impact of Duty Hour Restrictions on Resident-Attending interactions: An exploratory study. BMC Med Educ. 2017 Jul 18;17(1):124.
  17, p. 124 2017
• American Journal of Obstetrics and Gynecology
  Erekson E, Murchison RL, Gerjevic KA, Meljen VT, Strohbehn K. Erekson E, Murchison RL, Gerjevic KA, Meljen VT, Strohbehn K. Major Postoperative Complications following Surgical Procedures for Pelvic Organ Prolapse: a secondary database analysis of the ACS NSQIP. Am J Obstet Gynecol. 2017 Nov;217(5):608.e1-608.e17.
  11/01/2017 2017